Literature DB >> 31200845

Tumor Location May Predict Adverse Pathology and Survival Following Definitive Treatment for Bladder Cancer: A National Cohort Study.

Adam B Weiner1, Anuj S Desai1, Joshua J Meeks2.   

Abstract

BACKGROUND: While urothelial carcinoma of the bladder is often considered a multifocal disease, the location of the dominant tumor may be prognostic.
OBJECTIVE: To determine the association between intravesical tumor location and both adverse pathological outcomes as well as overall survival. DESIGN, SETTINGS, AND PARTICIPANTS: Patients in the National Cancer Database (2010-2015) with nonmetastatic urothelial carcinoma of the bladder who underwent primary treatment with radical cystectomy (RC; n=3464) or chemoradiotherapy (CRT; n=699). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable logistic regressions assessed the prognostic ability of tumor location to predict adverse pathology at RC (nodal metastases [pN+] or advanced stage [pT3-4]). Cox regressions were used to determine the effect of tumor location on overall survival in patients treated with RC or CRT. RESULTS AND LIMITATIONS: Following RC, 822 (24%) patients were pN+ and 1551 (55%) were pT3-4. Trigonal tumors were most likely to have adverse pathology (31% pN+ and 59% pT3-4), while anterior wall tumors were the least (19% pN+ and 50% pT3-4). Relative to the anterior wall, trigone (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.12-2.43, p=0.012) and bladder neck (OR 1.79, 95% CI 1.11-2.90, p=0.018) tumors were associated with increased odds of pN+ and dome (OR 1.56, 95% CI 1.08-2.24, p=0.017) with pT3-4. In those patients treated with primary CRT, trigone involvement was associated with worse survival (HR 1.58, 95% CI 1.17-2.13, p=0.003). Limitations included unmeasured variables and a relatively few number of patients with certain tumor locations.
CONCLUSIONS: Trigone and bladder neck tumors are associated with increased odds of nodal involvement, and dome with a higher tumor stage at RC. Patients with trigone involvement may have worse overall survival following CRT. PATIENT
SUMMARY: Location of the tumor within the bladder may be associated with worse cancer staging at the time of the surgery and worse survival following chemoradiotherapy.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystectomy; Epidemiology; Survival; Therapeutics; USA; Urinary bladder neoplasms

Mesh:

Year:  2018        PMID: 31200845     DOI: 10.1016/j.euo.2018.08.018

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  5 in total

1.  Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor.

Authors:  Seung-Hwan Jeong; Jang Hee Han; Chang Wook Jeong; Hyeon Hoe Kim; Cheol Kwak; Hyeong Dong Yuk; Ja Hyeon Ku
Journal:  BMC Cancer       Date:  2022-06-08       Impact factor: 4.638

2.  Cell-Level Spatio-Temporal Model for a Bacillus Calmette-Guérin-Based Immunotherapy Treatment Protocol of Superficial Bladder Cancer.

Authors:  Teddy Lazebnik
Journal:  Cells       Date:  2022-08-02       Impact factor: 7.666

Review 3.  Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.

Authors:  Di Maria Jiang; Peter Chung; Girish S Kulkarni; Srikala S Sridhar
Journal:  Curr Oncol Rep       Date:  2020-02-01       Impact factor: 5.075

4.  Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients.

Authors:  Xiangpeng Zhan; Ju Guo; Luyao Chen; Wen Deng; Xiaoqiang Liu; Ke Zhu; Weipeng Liu; Bin Fu
Journal:  Cancer Med       Date:  2021-08-23       Impact factor: 4.452

5.  Risk factors and nomogram for newly diagnosis of bone metastasis in bladder cancer: A SEER-based study.

Authors:  Zhiyi Fan; Zhangheng Huang; Chuan Hu; Yuexin Tong; Chengliang Zhao
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.